| Size | Price | Stock | Qty |
|---|---|---|---|
| 25g |
|
||
| Other Sizes |
| Targets |
NMDA (N-methyl-D-aspartic acid) receptor. N-Methyl-DL-aspartic acid is a glutamate analogue and a NMDA receptor agonist.
|
|---|---|
| ln Vitro |
N-Methyl-DL-aspartic acid is a glutamate analogue and a NMDA receptor agonist. As an agonist, it binds to the glutamate binding site on the NMDA receptor and activates the receptor, leading to an influx of calcium ions and downstream signaling events. This activation can modulate synaptic plasticity, learning, and memory. The compound is a racemic mixture, with the D-form being the active isomer.
|
| ln Vivo |
In vivo, N-Methyl-DL-aspartic acid can be used to study the effects of NMDA receptor activation on behavior and physiology. As an NMDA receptor agonist, it can induce excitotoxicity, seizures, and other neurological effects. It is used in research to model neurological diseases and to study the mechanisms of excitotoxicity.
|
| Enzyme Assay |
In vitro receptor binding assays for N-Methyl-DL-aspartic acid are performed to evaluate its affinity for the NMDA receptor. Radioligand binding studies using membrane preparations from brain tissue or cells expressing NMDA receptors are conducted. The compound's ability to displace a specific radiolabeled glutamate site ligand, such as [3H]-CGP 39653 or [3H]-MK-801, is measured to calculate its binding affinity.
|
| Cell Assay |
In vitro cell-based assays are conducted using neurons or cell lines expressing NMDA receptors. The cells are treated with N-Methyl-DL-aspartic acid, and receptor activation is measured by assessing downstream signaling events such as calcium mobilization or electrophysiological responses. The potency of the compound as an NMDA agonist is determined from these functional assays.
|
| Animal Protocol |
In vivo animal studies are conducted to evaluate the effects of NMDA receptor activation by N-Methyl-DL-aspartic acid. The compound is typically administered via intracerebroventricular or systemic injection. Its effects on seizure activity, excitotoxicity, and behavior are assessed in rodent models. These studies help to understand the role of NMDA receptors in various neurological and psychiatric disorders.
|
| ADME/Pharmacokinetics |
No detailed pharmacokinetic data are publicly available for N-Methyl-DL-aspartic acid. As a small, polar amino acid analog, its oral bioavailability is likely limited, and it may not readily cross the blood-brain barrier. The compound's pharmacokinetic properties would be studied in preclinical models to guide in vivo experiments if needed.
|
| Toxicity/Toxicokinetics |
No specific toxicity data are publicly available for N-Methyl-DL-aspartic acid. As an NMDA receptor agonist, its toxicity profile is related to its mechanism of action. Excessive NMDA receptor activation can lead to excitotoxicity, which can cause neuronal damage and death. At high doses, it can induce seizures and other neurological effects.
|
| References |
|
| Additional Infomation |
N-Methyl-DL-aspartic acid is a derivative of aspartic acid.
See also: N-Methyl-L-aspartic acid (note moved to). N-Methyl-DL-aspartic acid is a glutamate analogue and a NMDA receptor agonist. It is used as a research tool to study NMDA receptor function and glutamatergic signaling, and can be used for neurological diseases research. The compound is a racemic mixture and is not approved for human therapeutic use. |
| Molecular Formula |
C5H9NO4
|
|---|---|
| Molecular Weight |
147.13
|
| Exact Mass |
147.053
|
| CAS # |
17833-53-3
|
| PubChem CID |
4376
|
| Appearance |
White to off-white solid powder
|
| Density |
1.3±0.1 g/cm3
|
| Boiling Point |
258.2±30.0 °C at 760 mmHg
|
| Flash Point |
110.0±24.6 °C
|
| Vapour Pressure |
0.0±1.1 mmHg at 25°C
|
| Index of Refraction |
1.494
|
| LogP |
-0.44
|
| Hydrogen Bond Donor Count |
3
|
| Hydrogen Bond Acceptor Count |
5
|
| Rotatable Bond Count |
4
|
| Heavy Atom Count |
10
|
| Complexity |
145
|
| Defined Atom Stereocenter Count |
0
|
| SMILES |
CNC(CC(=O)O)C(=O)O
|
| InChi Key |
HOKKHZGPKSLGJE-UHFFFAOYSA-N
|
| InChi Code |
InChI=1S/C5H9NO4/c1-6-3(5(9)10)2-4(7)8/h3,6H,2H2,1H3,(H,7,8)(H,9,10)
|
| Chemical Name |
2-(methylamino)butanedioic acid
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
H2O: 16.67 mg/mL (113.30 mM)
DMSO: 4.17 mg/mL (28.34 mM) |
|---|---|
| Solubility (In Vivo) |
Solubility in Formulation 1: ≥ 0.42 mg/mL (2.85 mM) (saturation unknown) in 10% DMSO + 40% PEG300 + 5% Tween80 + 45% Saline (add these co-solvents sequentially from left to right, and one by one), clear solution.
For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 4.2 mg/mL clear DMSO stock solution to 400 μL PEG300 and mix evenly; then add 50 μL Tween-80 to the above solution and mix evenly; then add 450 μL normal saline to adjust the volume to 1 mL. Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH₂ O to obtain a clear solution. Solubility in Formulation 2: ≥ 0.42 mg/mL (2.85 mM) (saturation unknown) in 10% DMSO + 90% (20% SBE-β-CD in Saline) (add these co-solvents sequentially from left to right, and one by one), clear solution. For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 4.2 mg/mL clear DMSO stock solution to 900 μL of 20% SBE-β-CD physiological saline solution and mix evenly. Preparation of 20% SBE-β-CD in Saline (4°C，1 week): Dissolve 2 g SBE-β-CD in 10 mL saline to obtain a clear solution. View More
Solubility in Formulation 3: ≥ 0.42 mg/mL (2.85 mM) (saturation unknown) in 10% DMSO + 90% Corn Oil (add these co-solvents sequentially from left to right, and one by one), clear solution. Solubility in Formulation 4: 16.67 mg/mL (113.30 mM) in PBS (add these co-solvents sequentially from left to right, and one by one), clear solution; with ultrasonication. |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 6.7967 mL | 33.9836 mL | 67.9671 mL | |
| 5 mM | 1.3593 mL | 6.7967 mL | 13.5934 mL | |
| 10 mM | 0.6797 mL | 3.3984 mL | 6.7967 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
